MedTrace Logo

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

NCT01324063 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2012-07-16

No results posted yet for this study

Summary

RATIONALE: Patient abstract not available

PURPOSE: Patient abstract not available

Conditions

Interventions

BIOLOGICAL

sargramostim

DRUG

amsacrine

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Robert A. Zittoun, MD · Hotel Dieu de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1986-11-30
Primary Completion
1994-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324063 on ClinicalTrials.gov